No Data
Sinotherapeutics Inc.'s (SHSE:688247) Shares May Have Run Too Fast Too Soon
Xuantai Pharmaceutical (688247.SH): The company did not implement a share buyback in December.
On January 1, Gelonghui announced that Xuantai Pharmaceutical (688247.SH) reported that by December 2024, the company had not implemented any share buybacks. As of December 31, 2024, the company had repurchased a total of 4.3361 million shares through the centralized bidding trading system of the Shanghai Exchange, accounting for 0.96% of the company's total equity. The highest purchase price was 8.98 yuan/share, the lowest was 7.40 yuan/share, and the total amount paid was 36.126 million yuan (excluding stamp duty, transaction commissions, and other transaction fees).
Xuantai Pharmaceutical (688247.SH): Carbonate Sevelamer Tablets and Maxitentan Tablets are expected to be selected for the national Pharmaceutical centralized procurement.
Xuantai Pharmaceutical (688247.SH) announced that recently, the company participated in the tenth batch of national organization Pharmaceutical centralized volume procurement...
Xuantai Pharmaceutical (688247.SH): The company's products are participating in the national organization for centralized volume-based procurement of Pharmaceuticals and are expected to be selected.
Gelonghui, on December 13, announced that Xuantai Pharmaceutical (688247.SH) participated in the bidding for the tenth batch of national organized pharmaceutical centralized procurement. According to the document "Announcement of Proposed Selected Results for National Pharmaceutical Centralized Procurement" released by the National Organized Pharmaceutical Joint Procurement Office on December 12, 2024, the company's products, carbonic acid seviram tablets and macitentan tablets (products developed in collaboration with Puji Biological Technology (Taizhou) Co., Ltd.), were selected for this centralized procurement, while posaconazole enteric-coated tablets and tofacitinib citric acid extended-release tablets were not selected for this centralized procurement. The proposed selection results for this centralized procurement are intended.
Express News | Sinotherapeutics Says Key Shareholder Plans to Unload up to 2.4264% Stake in Company Within Three Months
We Think That There Are Some Issues For Sinotherapeutics (SHSE:688247) Beyond Its Promising Earnings
No Data
